GEN1286

Overview

GEN1286 is a bispecific antibody-drug conjugate (ADC) co-targeting EGFR and MET. It is designed to prevent escape via MET-driven compensatory signaling that arises upon EGFR inhibition, a known resistance mechanism in NPC and other EGFR-driven cancers.

Evidence in the corpus

• Cited as an EGFR×MET bispecific ADC under clinical investigation in R/M NPC, where MET compensatory activation is implicated in EGFR-inhibitor resistance PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.